

## QIBA FDG-PET/CT Biomarker Committee (BC) Call

01 November 2019 at 9 AM CT

Call Summary

### In attendance:

<i>Rathan Subramaniam, MD, PhD, MPH (Co-Chair)</i>	Martin Lodge, PhD	Anne Smith, PhD	<b>RSNA</b> Joe Koudelik
Adriaan Lammertsma, PhD	Nancy Obuchowski, PhD	Richard Wahl, MD	Julie Lisiecki

**Moderator:** Dr. Subramaniam

### Leadership announcement:

- Dr. Wahl congratulated Dr. Subramaniam on his new position as Dean of the University of Otago Medical School in New Zealand, commencing January 2020
- Dr. Subramaniam intends to keep up with his duties as QIBA FDG-PET/CT BC co-chair and hopes to recruit new QIBA participants
  - To accommodate this, a time change to the standing BC call would be needed

### QIBA NM Modality Poster for RSNA 2019:

- The focus of the posters this year has been changed to appeal to the broader radiological community and illustrate the value of QI and impact of QIBA
- Dr. Sunderland has created a poster for the NM modality; Dr. Subramaniam approved the poster for printing
- RSNA Staff to send a reminder to all nuclear medicine attendees regarding the [Meet-the-Expert sessions](#) and need for volunteers

### Trial implementation progress:

- The FDG-PET BC would like endorsement from the National Clinical Trials Network (NCTN) at the National Cancer Institute (NCI) to include the Profile as a requirement or benchmark for FDG clinical trials.
- An FDG Pilot group is working with the QIBA SIG to transform the checklist into a conformance document
- Dr. Kinahan and Dr Subramaniam discussed including the checklist as a survey in 3 or 4 NCTN clinical trials in the recent fall ECOG-ACRIN meeting.
- No standard protocols exist yet for SPECT/CT; protocols are still being developed that should incorporate multiple QIBA performance elements
- Dr. Subramaniam thinks that the best option may be an RO1 grant to fund a potential trial using SUVmax
- Per observations made during Dr. Wahl's trip to China, SUVmax is still quite variable and used in high matrix studies
  - The only way to find out if SUVmax performance has improved would be to conduct a trial
  - Reproducibility testing is needed
  - Commercially sponsored new tracer agents, such as gallium PSMA and DOTATOC, could be considered to improve measurement repeatability

### Proposed agenda items for the Breakout Session at RSNA 2019:

- RO1 proposal for a clinical trial with FDG-PET/CT
- NCTN trials
- SPECT/CT protocols needed for clinical trials
- Establishing quantitative parameters for new PET/CT radiopharmaceuticals in clinical practice
- Implementing the FDG-PET/CT Profile in multi-center trials

**Nuclear Medicine Schedule:** The next scheduled QIBA calls will be as follows at **9 am CT** unless otherwise noted:

<b>11/08</b>	Print copy deadline for QIBA CC posters
<b>11/15</b>	NM Q4 Coordinating Committee
<b>11/22</b>	NM Leadership – TBD
<b>12/13</b>	PET Amyloid BC – TBD
<b>12/20</b>	NM Leadership – TBD
<b>01/10</b>	PET Amyloid BC – TBD
<b>01/14</b>	SPECT TC <sup>99m</sup> BC @ 2 pm CT
<b>01/24</b>	NM Leadership – TBD

---

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible. Call participants are welcome to contact RSNA staff at [QIBA@RSNA.org](mailto:QIBA@RSNA.org) if their attendance is not reflected on the call summaries.